SFSilka Dawn Freiesleben

Silka Dawn Freiesleben

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Silka Dawn Freiesleben has a total of 133 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A computational ontology framework for the synthesis of multi-level pathology reports from brain MRI scans

    by Devesh Singh, Alice Grazia, Achim Reiz, Andreas Hermann, Slawek Altenstein, Lukas Beichert, Alexander Bernhardt, Katharina Buerger, Michaela Butryn, Peter Dechent, et al.

    Background: Convolutional neural network (CNN) based volumetry of MRI data can help differentiate Alzheimer's disease (AD) and the behavioral variant of frontotemporal dementia (bvFTD) as causes of cognitive decline and dementia. However, existing CNN-based MRI volumetry tools lack a structured hierarchical representation of brain anatomy, which would allow for aggregating regional pathological information and automated computational inference. Objective: Develop a computational ontology pipeline for quantifying hierarchical pathological abnormalities and visualize summary charts for brain atrophy findings, aiding differential diagnosis. Methods: Using FastSurfer, we segmented brain regions and measured volume and cortical thickness from MRI scans pooled across multiple cohorts (N = 3433; ADNI, AIBL, DELCODE, DESCRIBE, EDSD, and NIFD), including healthy controls, prodromal and clinical AD cases, and bvFTD cases. Employing the Web Ontology Language (OWL), we built a semantic model encoding hierarchical anatomical information. Additionally, we created summary visualizations based on sunburst plots for visual inspection of the information stored in the ontology. Results: Our computational framework dynamically estimated and aggregated regional pathological deviations across different levels of neuroanatomy abstraction. The disease similarity index derived from the volumetric and cortical thickness deviations achieved an AUC of 0.88 for separating AD and bvFTD, which was also reflected by distinct atrophy profile visualizations. Conclusions: The proposed automated pipeline facilitates visual comparison of atrophy profiles across various disease types and stages. It provides a generalizable computational framework for summarizing pathologic findings, potentially enhancing the physicians’ ability to evaluate brain pathologies robustly and interpretably.


  • Open Access

    Blood-based quantification of Aβ oligomers indicates impaired clearance from brain in ApoE ε4 positive subjects

    by Lara Blömeke, Fabian Rehn, Marlene Pils, Victoria Kraemer-Schulien, Anneliese Cousin, Janine Kutzsche, Tuyen Bujnicki, Silka D. Freiesleben, Luisa-Sophie Schneider, Lukas Preis, et al.

    Background: Quantification of Amyloid beta (Aβ) oligomers in plasma enables early diagnosis of Alzheimer’s Disease (AD) and improves our understanding of underlying pathologies. However, quantification necessitates an extremely sensitive and selective technology because of very low Aβ oligomer concentrations and possible interference from matrix components. Methods: In this report, we developed and validated a surface-based fluorescence distribution analysis (sFIDA) assay for quantification of Aβ oligomers in plasma. Results: The blood-based sFIDA assay delivers a sensitivity of 1.8 fM, an inter- and intra-assay variation below 20% for oligomer calibration standards and no interference with matrix components. Quantification of Aβ oligomers in 359 plasma samples from the DELCODE cohort reveals lower oligomer concentrations in subjective cognitive decline and AD patients than healthy Control participants. Conclusions: Correlation analysis between CSF and plasma oligomer concentrations indicates an impaired clearance of Aβ oligomers that is dependent on the ApoE ε4 status.


  • Association of Neurogranin and BACE1 With Clinical Cognitive Decline in Individuals With Subjective Cognitive Decline

    by Xiao Wang, Silka D. Freiesleben, Luisa-Sophie Schneider, Lukas Preis, Josef Priller, Eike J. Spruth, Slawek Altenstein, Anja Schneider, Klaus Fliessbach, Jens Wiltfang, et al.

    CSF biomarkers have immense diagnostic and prognostic potential for Alzheimer disease (AD). However, AD is still diagnosed relatively late in the disease process, sometimes even years after the initial manifestation of cognitive symptoms. Thus, further identification of biomarkers is required to detect related pathology in the preclinical stage and predict cognitive decline. Our study aimed to assess the association of neurogranin and β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) with cognitive decline in individuals with subjective cognitive decline (SCD). We enrolled participants with available neurogranin and BACE1 measurements in CSF from the DELCODE (DZNE-Longitudinal Cognitive Impairment and Dementia, Germany) cohort. The longitudinal change of Preclinical Alzheimer's Cognitive Composite score was assessed as the primary outcome in participants with SCD and controls. The secondary outcome was defined as conversion of SCD to mild cognitive impairment (MCI) during follow-up. Levels of neurogranin, BACE1, and neurogranin/BACE1 ratio across groups were compared by analysis of covariance after adjustment for demographics. The linear mixed-effects model and Cox regression analysis were applied to evaluate their association with cognitive decline and progression of SCD to MCI, respectively. A total of 530 participants (mean age: 70.76 ± 6.01 years, 48.7% female) were analyzed in the study. The rate of cognitive decline was faster in individuals with SCD with higher neurogranin and neurogranin/BACE1 ratio (β = -0.138, SE = 0.065, p = 0.037, and β = -0.293, SE = 0.115, p = 0.013). Higher baseline neurogranin and neurogranin/BACE1 ratio were associated with an increased rate of conversion from SCD to MCI (hazard ratio [HR] 1.35 per SD, 95% CI 1.03-1.77, p = 0.028, and HR 1.53 per SD, 95% CI 1.13-2.07, p = 0.007). In addition, the impact of higher neurogranin levels on accelerating the rate of cognitive decline was more pronounced in the SCD group than in cognitively unimpaired controls (β = -0.077, SE = 0.033, p = 0.020). Our findings suggest that CSF neurogranin and BACE1 begin to change in the preclinical stage of AD and they are associated with clinical progression in individuals with SCD.


  • Open Access

    A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings

    by Hannah Baumeister, Jacob W Vogel, Philip S Insel, Luca Kleineidam, Steffen Wolfsgruber, Melina Stark, Helena M Gellersen, Renat Yakupov, Matthias C Schmid, Falk Lüsebrink, et al.

    Memory clinic patients are a heterogeneous population representing various aetiologies of pathological aging. It is unknown if divergent spatiotemporal progression patterns of brain atrophy, as previously described in Alzheimer’s disease (AD) patients, are prevalent and clinically meaningful in this group of older adults. To uncover distinct atrophy subtypes, we applied the Subtype and Stage Inference (SuStaIn) algorithm to baseline structural MRI data from 813 participants enrolled in the DELCODE cohort (mean ± SD age = 70.67 ± 6.07 years, 52% females). Participants were cognitively unimpaired (CU; n = 285) or fulfilled diagnostic criteria for subjective cognitive decline (SCD; n = 342), mild cognitive impairment (MCI; n = 118), or dementia of the Alzheimer’s type (n = 68). Atrophy subtypes were compared in baseline demographics, fluid AD biomarker levels, the Preclinical Alzheimer Cognitive Composite (PACC-5), as well as episodic memory and executive functioning. PACC-5 trajectories over up to 240 weeks were examined. To test if baseline atrophy subtype and stage predicted clinical trajectories before manifest cognitive impairment, we analysed PACC-5 trajectories and MCI conversion rates of CU and SCD participants. Limbic-predominant and hippocampal-sparing atrophy subtypes were identified. Limbic-predominant atrophy first affected the medial temporal lobes, followed by further temporal and, finally, the remaining cortical regions. At baseline, this subtype was related to older age, more pathological AD biomarker levels, APOE ε4 carriership, and an amnestic cognitive impairment. Hippocampal-sparing atrophy initially occurred outside the temporal lobe with the medial temporal lobe spared up to advanced atrophy stages. This atrophy pattern also affected individuals with positive AD biomarkers and was associated with more generalised cognitive impairment. Limbic-predominant atrophy, in all and in only unimpaired participants, was linked to more negative longitudinal PACC-5 slopes than observed in participants without or with hippocampal-sparing atrophy and increased the risk of MCI conversion. SuStaIn modelling was repeated in a sample from the Swedish BioFINDER-2 cohort. Highly similar atrophy progression patterns and associated cognitive profiles were identified. Cross-cohort model generalizability, both on the subject and group level, were excellent, indicating reliable performance in previously unseen data. The proposed model is a promising tool for capturing heterogeneity among older adults at early at-risk states for AD in applied settings. The implementation of atrophy subtype- and stage-specific end-points may increase the statistical power of pharmacological trials targeting early AD.


  • Linking early-life bilingualism and cognitive advantage in older adulthood

    by Tommaso Ballarini, Elizabeth Kuhn, Sandra Röske, Slawek Altenstein, Claudia Bartels, Friederike Buchholz, Katharina Buerger, Peter Dechent, Laura Dobisch, Michael Ewers, et al.